Suicidal Ideation Secondary to Sodium Oxybate

To the Editor: Sodium oxybate is a derivate of gamma-hydroxybutyric acid (GHB). GHB is a short-chain fatty acid, a natural metabolite of the brainstem, with action as an inhibitory neurotransmitter or neuromodulator. Sodium oxybate is approved in Europe and considered the first-line therapy for the treatment of cataplexy in patients with narcolepsy-cataplexy syndrome, 1 and it is the only medication demonstrated to improve multiple major symptoms of the disease. In randomized, double-blind, placebo-controlled clinical trials, sodium oxybate was well tolerated,